April 12, 2026 a 08:38 am
MDT: Analysts Ratings - Medtronic plc
Medtronic plc, a leading medical device company, continues to showcase stable performance amidst market challenges. With a diverse product portfolio and global operations, its stock garners attention from analysts. Analysts' ratings reflect cautious optimism, balancing between growth prospects and industry headwinds.
Historical Stock Grades
The following table presents the most recent analyst ratings and visualization for Medtronic plc. The majority of analysts maintain a 'Buy' sentiment, underpinned by 14 'Buy' ratings and 4 'Strong Buy'. The absence of 'Sell' or 'Strong Sell' ratings reflects positive market sentiment.
| Recommendation | Count | Score Bar |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 14 | |
| Hold | 12 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment development
Recent months indicate a shift towards more cautious optimism. Although 'Strong Buy' ratings decreased slightly, the overall 'Buy' sentiment remains strong. The steady 'Hold' category suggests cautious market sentiment without drastic expectation changes:
- Total ratings demonstrate stability, with an emphasis on 'Buy' recommendations.
- Slight decrease in 'Strong Buy' from 5 to 4 in recent months.
- 'Hold' ratings remain consistent, highlighting consistent market sentiment.
Percentage trends
There is a visible shift in sentiment with a slight decrease in confidence among analysts. As 'Strong Buy' ratings dropped, 'Hold' and 'Buy' categories absorbed this change, indicating a more cautious stance amid potential industry volatility:
- Strong Buy ratings fell by 11% over the last year.
- Buy ratings, although dominant, have displayed minor fluctuations.
- 'Hold' positions consistently reflect market caution, presently accounting for approximately 30% of ratings.
- The absence of 'Sell' indicates analysts' confidence in Medtronic's long-term performance.
Latest Analyst Recommendations
Recent analyst recommendations display consistency in ratings with a continuation of current investment advice. Notably, upgrades and downgrades are sparse, reflecting stable market perspectives:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-09 | Outperform | Outperform | Evercore ISI Group |
| 2026-04-07 | Buy | Buy | Citigroup |
| 2026-04-06 | Outperform | Outperform | Evercore ISI Group |
| 2026-04-06 | Buy | Buy | Argus Research |
| 2026-04-01 | Neutral | Neutral | Piper Sandler |
Analyst Recommendations with Change of Opinion
Analysts occasionally shift their perspectives, hinting at evolving market conditions. Upgrades are more prevalent, suggesting increased confidence from a previously cautious outlook:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-09 | Buy | Hold | Needham |
| 2026-01-06 | Outperform | Market Perform | William Blair |
| 2025-11-19 | Neutral | Sell | Goldman Sachs |
| 2025-06-30 | Peer Perform | Underperform | Wolfe Research |
| 2025-03-04 | Buy | Neutral | Citigroup |
Interpretation
The prevailing analytical consensus around Medtronic suggests a cautious optimism with analysts generally maintaining their positions. While upgrades signify underlying confidence, the restrained rise in 'Hold' highlights wariness given the industry's inherent uncertainties. The stability in recommendations affirms Medtronic’s resilience, with potential for growth offset by macroeconomic and sector-specific challenges.
Conclusion
Medtronic remains a company under close watch by financial analysts, characterized by a solid 'Buy' consensus signaling confidence in its longer-term performance. However, subtle shifts toward 'Hold' ratings hint at potential caution amidst global economic changes. The consistent analyst sentiment underscores Medtronic's established market position but emphasizes the need for strategic vigilance. Investors should weigh these insights in their decision-making to navigate the prospects and challenges associated with Medtronic's stock offerings.